Genmab Upbeat About Advancing Acasunlimab As BioNTech Exits

Analysts are split on the future for acasunlimab after the German biotech pulled out of co-development but Genmab is all set to kick off a Phase III trial in metastatic non-small-cell lung cancer for the bispecific antibody which acts on 4-1BB, a receptor expressed on activated T cells and natural killer cells.